361 related articles for article (PubMed ID: 15927084)
1. Peptide inhibitors of dengue virus and West Nile virus infectivity.
Hrobowski YM; Garry RF; Michael SF
Virol J; 2005 Jun; 2():49. PubMed ID: 15927084
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.
Chu JJH; Rajamanonmani R; Li J; Bhuvanakantham R; Lescar J; Ng ML
J Gen Virol; 2005 Feb; 86(Pt 2):405-412. PubMed ID: 15659760
[TBL] [Abstract][Full Text] [Related]
3. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
4. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094
[TBL] [Abstract][Full Text] [Related]
5. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
Cregar-Hernandez L; Jiao GS; Johnson AT; Lehrer AT; Wong TA; Margosiak SA
Antivir Chem Chemother; 2011 May; 21(5):209-17. PubMed ID: 21566267
[TBL] [Abstract][Full Text] [Related]
6. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
7. Release of dengue virus genome induced by a peptide inhibitor.
Lok SM; Costin JM; Hrobowski YM; Hoffmann AR; Rowe DK; Kukkaro P; Holdaway H; Chipman P; Fontaine KA; Holbrook MR; Garry RF; Kostyuchenko V; Wimley WC; Isern S; Rossmann MG; Michael SF
PLoS One; 2012; 7(11):e50995. PubMed ID: 23226444
[TBL] [Abstract][Full Text] [Related]
8. Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.
McAuley AJ; Torres M; Plante JA; Huang CY; Bente DA; Beasley DWC
J Virol; 2016 May; 90(9):4757-4770. PubMed ID: 26912625
[TBL] [Abstract][Full Text] [Related]
9. Structural optimization and de novo design of dengue virus entry inhibitory peptides.
Costin JM; Jenwitheesuk E; Lok SM; Hunsperger E; Conrads KA; Fontaine KA; Rees CR; Rossmann MG; Isern S; Samudrala R; Michael SF
PLoS Negl Trop Dis; 2010 Jun; 4(6):e721. PubMed ID: 20582308
[TBL] [Abstract][Full Text] [Related]
10. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate.
Schmidt AG; Yang PL; Harrison SC
PLoS Pathog; 2010 Apr; 6(4):e1000851. PubMed ID: 20386713
[TBL] [Abstract][Full Text] [Related]
11. Computational identification of self-inhibitory peptides from envelope proteins.
Xu Y; Rahman NA; Othman R; Hu P; Huang M
Proteins; 2012 Aug; 80(9):2154-68. PubMed ID: 22544824
[TBL] [Abstract][Full Text] [Related]
12. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
13. Peptide inhibitors of flavivirus entry derived from the E protein stem.
Schmidt AG; Yang PL; Harrison SC
J Virol; 2010 Dec; 84(24):12549-54. PubMed ID: 20881042
[TBL] [Abstract][Full Text] [Related]
14. Antiviral peptides targeting the west nile virus envelope protein.
Bai F; Town T; Pradhan D; Cox J; Ashish ; Ledizet M; Anderson JF; Flavell RA; Krueger JK; Koski RA; Fikrig E
J Virol; 2007 Feb; 81(4):2047-55. PubMed ID: 17151121
[TBL] [Abstract][Full Text] [Related]
15. In vitro analysis of synthetic peptides in blocking the entry of dengue virus.
John AM; Jittmittraphap A; Chattanadee S; Alwin Prem Anand A; Shenbagarathai R; Leaungwutiwong P
Virus Res; 2019 Jan; 260():142-150. PubMed ID: 30508603
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of dengue virus entry into target cells using synthetic antiviral peptides.
Alhoot MA; Rathinam AK; Wang SM; Manikam R; Sekaran SD
Int J Med Sci; 2013; 10(6):719-29. PubMed ID: 23630436
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of dengue-virus entry.
Schmidt AG; Lee K; Yang PL; Harrison SC
PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653
[TBL] [Abstract][Full Text] [Related]
18. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
19. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.
Piñón JD; Kelly SM; Price NC; Flanagan JU; Brighty DW
J Virol; 2003 Mar; 77(5):3281-90. PubMed ID: 12584351
[TBL] [Abstract][Full Text] [Related]
20. Zika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other Flaviviruses.
Goo L; Dowd KA; Smith AR; Pelc RS; DeMaso CR; Pierson TC
mBio; 2016 Sep; 7(5):. PubMed ID: 27601578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
